Fig. 4

Fig. 4 Sunitinib malate significantly improves visual function and reduces VEGF expression in vhl−/− larvae. A) Gross morphology of sibling and vhl-/- larvae treated with increasing doses of sunitinib malate at 5 dpf. Treatment reduces yolk and cardiac oedema but does not result in swim bladder inflation. B) All concentrations of sunitinib tested increase OKR visual function at 5 dpf with 1 μM sunitinib malate highlighting a statistically significant improvement. n = 3, 12 technical replicates per experiment. C) Correlation between hyaloid vessel number and visual function in 5 dpf wildtype larvae treated with sunitinib malate. n = 3 with 10 technical replicates per experiment. Dotted line denotes vhl−/− visual function and number of primary hyaloid branches at 5 dpf. D) VMR Max ‘ON’ response is significantly increased dose dependently in larvae treated with 0.2 μM and 0.5 μM Sunitinib. n = 3, 12 technical replicates per treatment group per experiment. E) VMR chromatograms illustrating the average Max ON and Max OFF peaks after treatment. F) Expression of pro- and anti-angiogenic vhl−/− larval eyes following sunitinib treatment.